<?xml version='1.0' encoding='utf-8'?>
<document id="30091858"><sentence text="Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers."><entity charOffset="94-104" id="DDI-PubMed.30091858.s1.e0" text="S-ketamine" /><entity charOffset="109-120" id="DDI-PubMed.30091858.s1.e1" text="Ticlopidine" /><pair ddi="false" e1="DDI-PubMed.30091858.s1.e0" e2="DDI-PubMed.30091858.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30091858.s1.e0" e2="DDI-PubMed.30091858.s1.e1" /></sentence><sentence text="Low-dose oral S-ketamine is increasingly used in chronic pain therapy, but extensive cytochrome P450 (CYP) mediated metabolism makes it prone to pharmacokinetic drug-drug interactions (DDIs)"><entity charOffset="14-24" id="DDI-PubMed.30091858.s2.e0" text="S-ketamine" /></sentence><sentence text=" In our study, concentration-time data from five studies were used to develop a semimechanistic model that describes the ticlopidine-mediated inhibition of S-ketamine biotransformation"><entity charOffset="121-132" id="DDI-PubMed.30091858.s3.e0" text="ticlopidine" /><entity charOffset="156-166" id="DDI-PubMed.30091858.s3.e1" text="S-ketamine" /><pair ddi="false" e1="DDI-PubMed.30091858.s3.e0" e2="DDI-PubMed.30091858.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30091858.s3.e0" e2="DDI-PubMed.30091858.s3.e1" /></sentence><sentence text=" A mechanistic model was implemented to account for reversible and time-dependent hepatic CYP2B6 inactivation by ticlopidine, which causes elevated S-ketamine exposure in vivo"><entity charOffset="113-124" id="DDI-PubMed.30091858.s4.e0" text="ticlopidine" /><entity charOffset="148-158" id="DDI-PubMed.30091858.s4.e1" text="S-ketamine" /><pair ddi="false" e1="DDI-PubMed.30091858.s4.e0" e2="DDI-PubMed.30091858.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30091858.s4.e0" e2="DDI-PubMed.30091858.s4.e1" /></sentence><sentence text=" A pharmacokinetic model was developed with gut wall and hepatic clearances for S-ketamine, its primary metabolite norketamine, and ticlopidine"><entity charOffset="80-90" id="DDI-PubMed.30091858.s5.e0" text="S-ketamine" /><entity charOffset="115-126" id="DDI-PubMed.30091858.s5.e1" text="norketamine" /><entity charOffset="132-143" id="DDI-PubMed.30091858.s5.e2" text="ticlopidine" /><pair ddi="false" e1="DDI-PubMed.30091858.s5.e0" e2="DDI-PubMed.30091858.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30091858.s5.e0" e2="DDI-PubMed.30091858.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30091858.s5.e0" e2="DDI-PubMed.30091858.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30091858.s5.e1" e2="DDI-PubMed.30091858.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30091858.s5.e1" e2="DDI-PubMed.30091858.s5.e2" /></sentence><sentence text=" Nonlinear mixed effects modeling approach was used (NONMEM version 7" /><sentence text="3" /><sentence text="0), and the final model was evaluated with visual predictive checks and the sampling-importance-resampling procedure" /><sentence text=" Our final model produces biologically plausible output and demonstrates that ticlopidine is a strong inhibitor of CYP2B6 mediated S-ketamine metabolism"><entity charOffset="78-89" id="DDI-PubMed.30091858.s9.e0" text="ticlopidine" /><entity charOffset="131-141" id="DDI-PubMed.30091858.s9.e1" text="S-ketamine" /><pair ddi="false" e1="DDI-PubMed.30091858.s9.e0" e2="DDI-PubMed.30091858.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30091858.s9.e0" e2="DDI-PubMed.30091858.s9.e1" /></sentence><sentence text=" Simulations from our model may be used to evaluate chronic pain therapy with S-ketamine"><entity charOffset="78-88" id="DDI-PubMed.30091858.s10.e0" text="S-ketamine" /></sentence><sentence text="" /></document>